Cipla Limited v. AstraZeneca Ab

Court

District Court, D. Delaware (D. Del.)
Official Court Website →

Assigned judge

Maryellen Noreika · 2,011 cases in index

Docket number

1:19-cv-00438

Cause

28:2201 Declaratory Judgment
28 U.S.C. § 2201 — Declaratory judgment

Nature of suit

835 Patent - Abbreviated New Drug Application(ANDA)
Hatch-Waxman patent disputes over a generic-drug (ANDA) application.

Jurisdiction

Federal Question

Jury demand

None

Date filed

03/01/2019

Date terminated

09/26/2019

1,117 Patent - ANDA cases in this court are indexed here.

Parties

• plaintiff · Cipla Limited · 55 cases
• defendant · Astrazeneca Ab · 185 cases

About Patent - ANDA Lawsuits

ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

Frequently Asked Questions

What is Cipla Limited v. AstraZeneca Ab?

Cipla Limited v. AstraZeneca Ab is a federal patent - anda lawsuit filed on 03/01/2019 in the District Court, D. Delaware. The case was terminated on 09/26/2019. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What type of case is this?

It is classified as “Patent - ANDA” under the federal nature-of-suit system. ANDA patent cases arise when a generic-drug maker files an Abbreviated New Drug Application and the brand-name patent holder sues for infringement under the Hatch-Waxman Act.

What court is the case in?

The case is in the District Court, D. Delaware, docket number 1:19-cv-00438.

When was the case filed?

Cipla Limited v. AstraZeneca Ab was filed on 03/01/2019. It was terminated on 09/26/2019.

What law is the case brought under?

The docket lists the cause as 28 U.S.C. § 2201 — Declaratory judgment.